Stock Events

Stock Events

Chugai Pharmaceutical 

$41.68
107
-$1.97-4.5% Thursday 19:32

Statistics

Day High
45
Day Low
45
52W High
68.08
52W Low
39.03
Volume
100
Avg. Volume
10,470
Mkt Cap
69.98B
P/E Ratio
27.31
Dividend Yield
1.94%
Dividend
0.81

Upcoming

31
DEC
Dividend Ex
Decreased
 
30
JUN 27
Dividend Ex
Estimated
 
31
DEC 27
Dividend Ex
Estimated
 
30
JUN 28
Dividend Ex
Estimated
 

Dividends

1.94%Dividend Yield
Jun 26
$0.41
Mar 26
$0.45
Mar 26
$0.47
Aug 25
$0.34
Aug 25
$0.51
10Y Growth
34.96%
5Y Growth
4.51%
3Y Growth
14.62%
1Y Growth
-54.18%

Earnings

24JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.34
0.4
0.46
0.52
Expected EPS
0.46539161526
Actual EPS
N/A

Financials

34.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
8.35BRevenue
2.88BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CHGCF. It's not an investment recommendation.
Japan Tobacco
21
2914.TSE
Itochu
21
8001.TSE
Microsoft
19
MSFT
NVIDIA
19
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. competes in various therapeutic areas including oncology, vaccines, and immunology, similar to Chugai's focus areas.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is a direct competitor in the oncology and immunology sectors, areas where Chugai is actively developing treatments.
Novartis
NVS
Mkt Cap293.94B
Novartis AG operates in the same therapeutic areas as Chugai, including oncology and rheumatology, making it a strong competitor.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the oncology, immunology, and neuroscience sectors.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca PLC has a strong presence in oncology, respiratory, and cardiovascular diseases, competing with Chugai's research and drug portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb Company competes in the oncology sector, particularly in developing treatments for cancer, a key area for Chugai.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline plc competes with Chugai in the areas of oncology and immunology, with a focus on developing innovative medicines and vaccines.
Sanofi
SNY
Mkt Cap104.13B
Sanofi competes across several of the same therapeutic areas as Chugai, including oncology, immunology, and rare diseases.
Takeda Pharmaceutical
TAK
Mkt Cap52.88B
Takeda Pharmaceutical Company Limited, as a major Japanese pharmaceutical, competes directly with Chugai in the domestic market across various therapeutic areas including oncology and gastroenterology.

About

Chugai Pharmaceutical Co., Ltd. is a Japan-headquartered global biopharmaceutical firm, engaged in the entire process of pharmaceutical product creation, from groundbreaking research and development to manufacturing, marketing, and worldwide distribution. Its extensive product portfolio targets critical health areas. In oncology, key offerings include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. For osteoporosis, it provides Actemra, Edirol, and Bonviva. Other specialized medications address conditions such as erythropoiesis (Mircera) and secondary hyperparathyroidism (Oxarol). Furthermore, Chugai offers treatments like Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng for a range of other significant diseases. The company maintains a robust pipeline of development candidates, focusing on innovation across therapeutic fields including oncology, immunology, neuroscience, hematology, and ophthalmology. Founded in 1925 and based in Chuo, Japan, Chugai operates as a subsidiary of Roche Holding Ltd., cultivating strategic alliances with the Roche Group and fostering collaborative research initiatives with academic partners.
Show more...
CEO
Dr. Osamu Okuda
Employees
7872
Country
Japan
ISIN
JP3519400000

Listings

STU
DE
CUP.STU
MU
DE
CUP.MU
MU
DE
CUP0.MU
OTC Link
US
CHGCF

0 Comments

Share your thoughts

FAQ

What is Chugai Pharmaceutical stock price today?▼
The current price of CHGCF is $41.68 USD — it has decreased by -4.5% in the past 24 hours. Watch Chugai Pharmaceutical stock price performance more closely on the chart.
What is Chugai Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Chugai Pharmaceutical stocks are traded under the ticker CHGCF.
Is Chugai Pharmaceutical stock price growing?▼
CHGCF stock has fallen by -10.26% compared to the previous week, the month change is a -9.06% fall, over the last year Chugai Pharmaceutical has showed a -11.3% decrease.
What is Chugai Pharmaceutical market cap?▼
Today Chugai Pharmaceutical has the market capitalization of 69.98B
What is Chugai Pharmaceutical revenue for the last year?▼
Chugai Pharmaceutical revenue for the last year amounts to 8.35B USD.
What is Chugai Pharmaceutical net income for the last year?▼
CHGCF net income for the last year is 2.88B USD.
Does Chugai Pharmaceutical pay dividends?▼
Yes, CHGCF dividends are paid semi-annual. The last dividend per share was 0.41 USD. As of today, Dividend Yield (FWD)% is 1.94%.
How many employees does Chugai Pharmaceutical have?▼
As of July 24, 2026, the company has 7,872 employees.
In which sector is Chugai Pharmaceutical located?▼
Chugai Pharmaceutical operates in the Health & Wellness sector.
When did Chugai Pharmaceutical complete a stock split?▼
The last stock split for Chugai Pharmaceutical was on July 06, 2020 with a ratio of 12:1.
Where is Chugai Pharmaceutical headquartered?▼
Chugai Pharmaceutical is headquartered in Chuo, Japan.